tradingkey.logo

Pharma firm SIGA Q2 product revenues rise

ReutersAug 5, 2025 8:09 PM


Overview

  • SIGA Q2 product revenues rise to $79 mln, driven by TPOXX sales

  • Company awarded $27 mln in BARDA 19C contract funding for development

  • Net income for Q2 jumps to $35.5 mln, reflecting strong performance


Result Drivers

  • TPOXX SALES - $53 mln from oral TPOXX and $26 mln from IV TPOXX sales to Strategic National Stockpile

  • BARDA FUNDING - $27 mln awarded for TPOXX pediatric program and manufacturing support under BARDA 19C contract


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

$0.49

Q2 Net Income

$35.50 mln


Analyst Coverage

  • The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nGNX7jGW8k

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI